Though most biological processes happen at the nano level, it wasn’t until recently that new technological advancements helped in opening up the possibility of nanomedicine to healthcare researchers and professionals. Today’s infographic, which comes to us from Best Health Degrees, highlights some of the most promising research in nanomedicine.
What is Nanotechnology?
Nanotechnology is the engineering of functional systems at the molecular level. The field combines elements of physics and molecular chemistry with engineering to take advantage of unique properties that occur at nanoscale. One practical example of this technology is the use of tiny carbon nanotubes to transport drugs to specific cells. Not only do these nanotubes have low toxicity and a stable structure, they’re an ideal container for transporting drugs directly to the desired cells.
Small Systems, Big Applications
While many people will be most familiar with nanotech as the technology powering Iron Man’s suit, real world breakthroughs at the nanoscale will soon be saving lives in healthcare. Here are a few ways nanotechnology is shaping the future of medical treatment:
1. Smart Pills
While smart pill technology is not a new idea — a “pill cam” was cleared by the FDA in 2001 — researchers are coming up with innovative new applications for the concept. For example, MIT researchers designed an ingestible sensor pill that can be wirelessly controlled. The pill would be a “closed-loop monitoring and treatment” solution, adjusting the dosage of a particular drug based on data gathered within the body (e.g. gastrointestinal system). An example of this technology in action is the recent FDA-approved smart pill that records when medication was taken. The product, which is approved for people living with schizophrenia and bipolar disorder, allows patients to track their own medication history through a smartphone, or to authorize physicians and caregivers to access that information online.
2. Beating the Big C
Nearly 40% of humans will be diagnosed with cancer at some point in their lifetime, so any breakthrough in cancer treatment will have a widespread impact on society. On the key issues with conventional chemotherapy and radiation treatments is that the body’s healthy cells can become collateral damage during the process. For this reason, researchers around the world are working on using nano particles to specifically target cancer cells. Oncology-related drugs have the highest forecasted worldwide prescription drug sales, and targeting will be a key element in the effectiveness of these powerful new drugs.
3. Diagnostics
Medical implants — such as knee and hip replacements — have improved the lives of millions, but a common problem with these implants is the risk of post-surgery inflammation and infection. In many cases, symptoms from an infection are detected so late that treatment is less effective, or the implant will need to be replaced all together. Nanoscale sensors embedded directly into the implant or surrounding area could detect infection much sooner. As targeted drug delivery becomes more feasible, it could be possible to administer treatment to an infected area at the first sign of infection. Examples like this show the true promise of nanotechnology in the field of medicine. Before long, gathering data from within the body and administering treatments in real-time could move from science fiction to the real world. – Professor Susan Lindquist on But fast forward to the end of last week, and SVB was shuttered by regulators after a panic-induced bank run. So, how exactly did this happen? We dig in below.
Road to a Bank Run
SVB and its customers generally thrived during the low interest rate era, but as rates rose, SVB found itself more exposed to risk than a typical bank. Even so, at the end of 2022, the bank’s balance sheet showed no cause for alarm.
As well, the bank was viewed positively in a number of places. Most Wall Street analyst ratings were overwhelmingly positive on the bank’s stock, and Forbes had just added the bank to its Financial All-Stars list. Outward signs of trouble emerged on Wednesday, March 8th, when SVB surprised investors with news that the bank needed to raise more than $2 billion to shore up its balance sheet. The reaction from prominent venture capitalists was not positive, with Coatue Management, Union Square Ventures, and Peter Thiel’s Founders Fund moving to limit exposure to the 40-year-old bank. The influence of these firms is believed to have added fuel to the fire, and a bank run ensued. Also influencing decision making was the fact that SVB had the highest percentage of uninsured domestic deposits of all big banks. These totaled nearly $152 billion, or about 97% of all deposits. By the end of the day, customers had tried to withdraw $42 billion in deposits.
What Triggered the SVB Collapse?
While the collapse of SVB took place over the course of 44 hours, its roots trace back to the early pandemic years. In 2021, U.S. venture capital-backed companies raised a record $330 billion—double the amount seen in 2020. At the time, interest rates were at rock-bottom levels to help buoy the economy. Matt Levine sums up the situation well: “When interest rates are low everywhere, a dollar in 20 years is about as good as a dollar today, so a startup whose business model is “we will lose money for a decade building artificial intelligence, and then rake in lots of money in the far future” sounds pretty good. When interest rates are higher, a dollar today is better than a dollar tomorrow, so investors want cash flows. When interest rates were low for a long time, and suddenly become high, all the money that was rushing to your customers is suddenly cut off.” Source: Pitchbook Why is this important? During this time, SVB received billions of dollars from these venture-backed clients. In one year alone, their deposits increased 100%. They took these funds and invested them in longer-term bonds. As a result, this created a dangerous trap as the company expected rates would remain low. During this time, SVB invested in bonds at the top of the market. As interest rates rose higher and bond prices declined, SVB started taking major losses on their long-term bond holdings.
Losses Fueling a Liquidity Crunch
When SVB reported its fourth quarter results in early 2023, Moody’s Investor Service, a credit rating agency took notice. In early March, it said that SVB was at high risk for a downgrade due to its significant unrealized losses. In response, SVB looked to sell $2 billion of its investments at a loss to help boost liquidity for its struggling balance sheet. Soon, more hedge funds and venture investors realized SVB could be on thin ice. Depositors withdrew funds in droves, spurring a liquidity squeeze and prompting California regulators and the FDIC to step in and shut down the bank.
What Happens Now?
While much of SVB’s activity was focused on the tech sector, the bank’s shocking collapse has rattled a financial sector that is already on edge.
The four biggest U.S. banks lost a combined $52 billion the day before the SVB collapse. On Friday, other banking stocks saw double-digit drops, including Signature Bank (-23%), First Republic (-15%), and Silvergate Capital (-11%).
Source: Morningstar Direct. *Represents March 9 data, trading halted on March 10.
When the dust settles, it’s hard to predict the ripple effects that will emerge from this dramatic event. For investors, the Secretary of the Treasury Janet Yellen announced confidence in the banking system remaining resilient, noting that regulators have the proper tools in response to the issue.
But others have seen trouble brewing as far back as 2020 (or earlier) when commercial banking assets were skyrocketing and banks were buying bonds when rates were low.
